This past weekend, we teamed up with @TackleCancer before the Dolphins took on the Jaguars to connect with fans and share more about Shield™, the blood test that screens for #ColonCancer the more pleasant way, while raising awareness about the importance of screening. A big

RT @HardRockStadium: Early screenings with @GuardantHealth x @TackleCancer at the Dolphins Fan Zone ‼️

Are you ready for some football. AND screening?. We’ll be with @TackleCancer before the Dolphins take on the Jaguars! Stop by our booth outside @HardRockStadium to learn about Shield™ - the blood test that screens for colon cancer the more pleasant way.

RT @FightCRC: It's more than a Climb. It's proof we'll never face #colorectalcancer alone. 💙 Since 2016, Climbers have raised $1M+ for rese….

RT @Biotech2050Pod: #Biotech2050 Episode is sponsored by @MeetClora .Can a blood test change how we detect & treat cancer? 💉 @GuardantHeal….

We’re proud to be teaming up with @AmericanCancer to expand cancer screenings in underserved communities, raising awareness and promoting early detection. Learn more about our partnership:

This week, we reported our second quarter 2025 financial results, achieving 31% year-over-year revenue growth. Strong performance across Oncology, Screening, and Biopharma & Data, combined with continued momentum from our Smart Liquid Biopsy platform, led us to raise our

James’s story is a powerful reminder: colorectal cancer doesn't always come with symptoms and early detection can save lives. His advocacy is helping spotlight how a simple blood draw from our Shield test is making screening easier and more accessible. Thank you to

We’re honored to partner with @vanderjames to raise awareness about the importance of #ColorectalCancer screening and our Shield™ blood test. Through our collaboration, we aim to reach millions of Americans aged 45 and older who are still unscreened.

RT @CRC_AACR: Just published:.Methylation-Based #ctDNA Tumor Fraction Changes Predict Long-term Clinical Benefit from #ImmuneCheckpointInhi….

We announced the first clinical readout from our collaboration in the RADIOHEAD study with @parkerici, showing that Guardant Reveal™ detects immunotherapy response in advanced cancer up to 5 months earlier than standard imaging.

Today we announced that the first patient has been enrolled in the @theNCI’s Vanguard Study, evaluating our Shield™ MCD test. The four-year study will assess the feasibility of using blood-based tests like Shield to detect multiple cancers in individuals without symptoms.

RT @Inside_PM: AI-Powered Oncology and Genomic Testing Converge with VieCure and Guardant Healthcare Partnership. @VieCure's partnership wi….

Our precision oncology tests are now integrated into the VieCure Halo Intelligence platform, giving oncologists streamlined access to critical insights and enabling community oncology practices to make faster, more personalized treatment decisions for their patients—without

Join us for a live #Webinar on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials. While genomic alterations provide critical insight into tumor biology, they often don’t tell the full story.

Last week, our co-CEO AmirAli Talasaz took the stage at #AspenIdeasHealth on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, and AI are reshaping the future of care. From expanding access to early

At #AspenIdeasHealth, our co-CEO AmirAli Talasaz sat down with @DrJohnTorres to discuss a critical gap in cancer care: screening technologies are advancing, but access isn’t keeping pace. Our FDA-approved Shield™ blood test has the potential to expand access to early detection

Today, our co-CEO AmirAli Talasaz joins the New Frontiers in Cancer panel at #AspenIdeasHealth to discuss how innovation in blood-based screening, AI, and precision medicine is reshaping the fight against cancer. Tune in via @AspenIdeas to join the conversation!